Omega is making steady progress with Visitect, an HIV monitoring point-of care (PoC) diagnostic, after initial field trials in India and Kenya. Further optimisation of Visitect is needed for the finger-stick blood samples. We have reduced our expectations for FY15 sales to £0.5m as the timetable for further optimisation and the next larger, 1,000-patient field studies have to be clarified. Allergy iSYS development is progressing to a 40-test launch menu, 24 tests are validated with eight of these transferred to manufacturing. Normalised FY14 PBT was £1.1m on revenue of £11.6m.

Unlock the rest of this Article in 15 seconds

or Unlock with your email